
The study evaluated the vaccine effectiveness of bivalent Covid-19 vaccines in over 6 million individuals and found that bivalent boosters provided significant additional protection for those who had previously been vaccinated. The researchers also estimated the number needed to vaccinate and the associated cost to avoid one severe Covid-19 outcome or death, with the lowest values in persons 65 years or older. However, the numbers for individuals 18 to 64 years of age appear to be much higher and raise concerns about the value of providing bivalent boosters to all 6 months or older individuals, prompting prioritization of those at the highest risk for severe disease.
Like
Save
Share